The purpose of this pilot study is to assess the efficacy, safety and tolerance profile of the enteral feeding product VITAL AF (a semi-elemental, high protein, and high omega-3 fish oil) when compared to Osmolite 1.2, a standard feeding product in critically ill and/or post surgical patients in the intensive care unit (ICU). If enough patients are recruited, inferences about impact on outcomes may also be drawn.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
50
Semi-elemental, high protein, and high omega-3 fish oil enteral formula
High protein enteral formula
NewYork-Presbyterian Hospital at Columbia University Medical Center
New York, New York, United States
Improved tolerance to enteral (tube) feeding
Measure incidence of diarrhea, nausea, vomiting, increased gastric residual, etc.
Time frame: Baseline and 21 Days
Improved delivery of prescribed calories
Measurement of volume of feeding product actually delivered to patient is part of the daily flow-sheet data.
Time frame: Baseline and 21 Days
Decreased incidence of complications
Measure incidence of diarrhea, nausea, vomiting, increased gastric residual, etc.
Time frame: Baseline and 21 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.